BCL2 and cancer: Immunofluorescence analysis corroborated these findings, demonstrating a significantly increase in BAX fluorescence intensity in cancer cells treated with anlotinib alone or in combination with DDP, while the fluorescence intensity of BCL2 was decreased (Figures 6A, B).